3 results on '"Retinal Vasculitis therapy"'
Search Results
2. [Retinal vasculitis and systemic diseases].
- Author
-
Gascon P, Jarrot PA, Matonti F, and Kaplanski G
- Subjects
- Behcet Syndrome complications, Behcet Syndrome diagnosis, Behcet Syndrome therapy, Humans, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic therapy, Multiple Sclerosis complications, Multiple Sclerosis diagnosis, Multiple Sclerosis therapy, Sarcoidosis complications, Sarcoidosis diagnosis, Sarcoidosis therapy, Autoimmune Diseases complications, Autoimmune Diseases diagnosis, Autoimmune Diseases therapy, Inflammation complications, Inflammation diagnosis, Inflammation therapy, Retinal Vasculitis diagnosis, Retinal Vasculitis etiology, Retinal Vasculitis therapy
- Abstract
Retinal vasculitis (RV) is an inflammation of retinal blood vessels that can be associated with uveitis or be isolated, and can induce vascular occlusion and retinal ischemia. Visual acuity can be severely affected in case of macular involvement or neovessel formation. The diagnosis relies on fundoscopy and fluorescein angiography. Systemic diseases may be associated with RV, the most frequently encountered are Behçet's disease, sarcoidosis or multiple sclerosis, all predominantly associated with venous involvement, whereas systemic lupus erythematosus and necrotizing vasculitis are less frequently observed and predominantly associated with arterial or mixed vasculitis. Treatments are usually aggressive in order to preserve a good visual acuity and to reduce retinal inflammation and chronic ischemia. Steroids, immunosuppressive drugs, retinal laser photocoagulation, intravitreal anti-VEGF injections are usual treatments and more recently, anti-TNFalpha monoclonal therapeutic antibodies have been shown to be very successful., (Copyright © 2018 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
3. [Eales' disease].
- Author
-
Errera MH, Pratas A, Goldschmidt P, Sedira N, Sahel JA, and Benesty J
- Subjects
- Adult, Humans, Laser Coagulation, Male, Tuberculosis, Ocular complications, Tuberculosis, Ocular epidemiology, Tuberculosis, Ocular therapy, Vitrectomy, Young Adult, Neovascularization, Pathologic diagnosis, Neovascularization, Pathologic epidemiology, Neovascularization, Pathologic etiology, Neovascularization, Pathologic therapy, Retinal Vasculitis diagnosis, Retinal Vasculitis epidemiology, Retinal Vasculitis etiology, Retinal Vasculitis therapy
- Abstract
The syndrome of recurrent vitreous hemorrhages in young men was described for the first time by Henry Eales in 1880. The association with a clinical manifestation of ocular inflammation was reported 5years later. Eales disease affects young adults who present with ischemic retinal vasculitis, with the peripheral retina most commonly affected. Most cases have been reported in South Asia. Although the etiology of this abnormality is unknown, it may be related to an immune sensitivity to Mycobacterium tuberculosis antigens. Its pathogenesis is related to extensive ischemia that affects the retina, secondary to an obliterative retinal vasculopathy with release of angiogenic factors of the VEGF type. Involvement of the retina is the hallmark of the disease, which manifests as follows: periphlebitis, retinal capillary ischemia most often affecting the periphery with secondary proliferative retinopathy and retinal and/or papillary neovascularization, recurrent vitreous hemorrhages and tractional retinal detachment. These complications are potentially blinding. The natural history of Eales disease varies, with temporary or permanent remission in some cases and continuous progression in others. Progression is often bilateral, which necessitates regular follow-up. The treatment of Eales disease depends on the stage of the disease and is not well defined. Observation only, pars plana vitrectomy surgery and/or intravitreal injections of anti-VEGF are recommended in cases of vitreous hemorrhage, associated with corticosteroids when retinal vasculitis is present. Laser pan-retinal photocoagulation is necessary when neovascularization is present., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.